Showing 4031-4040 of 5623 results for "".
- Cellusion and Minaris Regenerative Medicine Enter Alliance for the Manufacturing of Corneal Endothelial Cell Regenerative Therapyhttps://modernod.com/news/cellusion-and-minaris-regenerative-medicine-enter-alliance-for-the-manufacturing-of-corneal-endothelial-cell-regenerative-therapy/2481170/Cellusion, a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem, and Minaris Regenerative Medicine, a global contract and development manufacturing organization, announced a Letter of Intent (LOI) of the Manufacturing of CLS001 for a cor
- Tarsus Announces Transition Plans for Board of Directorshttps://modernod.com/news/tarsus-announces-transition-plans-for-board-of-directors/2481168/Tarsus Pharmaceuticals announced several expected upcoming transitions to its Board of Directors by year-end. Tarsus Co-Founder and Chairman, Michael Ackermann, PhD, plans to transition off the Board of Directors. Upon Dr. Ackermann’s planned transition, Wendy Yarno, industry veteran and cu
- PatientPoint Acquires Rendia to Accelerate Expansion into Ophthalmology Specialtyhttps://modernod.com/news/patientpoint-acquires-rendia-to-accelerate-expansion-into-ophthalmology-specialty/2481166/PatientPoint announced the acquisition of Rendia, a provider of point-of-care content for eye care providers sold on a subscription basis. Terms of the deal were not disclosed. With PatientPoint’s expansion into ophthalmology and optometry, PatientPoint’
- Researchers Discover New Molecular Driver of Retinoblastomahttps://modernod.com/news/researchers-discover-new-molecular-driver-of-retinoblastoma/2481163/Despite decades of medical advances, children who develop the pediatric eye cancer retinoblastoma often lose their vision or an eye due to a lack of specific, targeted therapies and a poor molecular understanding of the cancer. Now researchers at UT Southwestern and the University of Miami have <
- Harrow Sells Non-Ophthalmic Compounding Businesshttps://modernod.com/news/harrow-sells-non-ophthalmic-compounding-business/2481162/Harrow announced the sale of its non‑ophthalmic compounding business to Innovation Compounding Pharmacy, LLC, an affiliate of Revelation Pharma Corporation. Financial terms of the deal were not disclosed. Revelation purchased the assets of Harrow’s non‑ophthalmic c
- Paladin Phase 4 Study Confirms Iluvien Patients' Reduced Need for Multiple Treatmentshttps://modernod.com/news/paladin-phase-4-study-confirms-iluvien-patients-reduced-need-for-multiple-treatments/2481156/Alimera Sciences announced that post-hoc analyses from the PALADIN phase 4 safety study demonstrate that median treatment frequency in diabetic macular edema (DME) patients treated with the Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg was lower than from patients on other re
- New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)https://modernod.com/news/new-data-reveal-molecular-drivers-of-thyroid-eye-disease-ted-may-remain-activated-in-patients-with-low-clinical-activity-score-cas/2481152/Horizon Therapeutics announced the presentation of new data defining molecular patterns in TED and further implicating the role of insulin-like growth factor-1 (IGF-1) in patients with low CAS. These data were presented during the American Academy of Ophthalmology Annual Meeting (
- Cellusion and Minaris Regenerative Medicine Enter into Business Alliance for the Manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative Therapyhttps://modernod.com/news/cellusion-and-minaris-regenerative-medicine-enter-into-business-alliance-for-the-manufacturing-of-cls001-for-a-corneal-endothelial-cell-regenerative-therapy/2481150/Cellusion, a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem, and Minaris Regenerative Medicine, a global contract and development manufacturing organization, announced a letter of intent (LOI) of the manufacturing of CLS001 for a cor
- Schwind Eye-Tech-Solutions Announces Management Changeshttps://modernod.com/news/schwind-eye-tech-solutions-announces-management-changes/2481149/Rolf Schwind, who was serving as CEO of Schwind eye-tech-solutions GmbH, has withdrawn from active leadership of the company, effective October 1, 2022, and joined the Advisory Board. In that capacity he will continue to contribute to the growth of Schwind with his more than 40 years of
- NovaSight Announces FDA 510(K) Clearance of CureSight Digital Therapy for Amblyopiahttps://modernod.com/news/novasight-announces-fda-510k-clearance-of-curesight-digital-therapy-for-amblyopia/2481148/NovaSight announced that the FDA has cleared CureSight, a digital therapy device for amblyopia (lazy eye). CureSight is an eye-tracking-based system aimed for improving visual acuity and stereo acuity by training the visual system to use both eyes simultaneously. The ground-breaking cle